Skip Navigation

European Journal of Heart Failure 2008 10(3):260-266; doi:10.1016/j.ejheart.2008.01.005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alehagen, U.
Right arrow Articles by Janzon, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alehagen, U.
Right arrow Articles by Janzon, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society of Cardiology

A clinician's experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting

U. Alehagen* and M. Janzon

Department of Cardiology, Heart Center, University Hospital of Linköping SE-581 85 Linköping, Sweden

* Corresponding author. Tel.: +46 13 22 20 00. E-mail address: urban.alehagen{at}ihs.liu.se (U. Alehagen).


  Abstract

The evaluation of natriuretic peptides has become increasingly valuable in a clinical setting, where information is often needed promptly.

Objectives: To compare the usefulness of the recently released Roche Cardiac Reader® NT-proBNP assay against the Roche Elecsys® NT-proBNP laboratory system in a clinical setting.

Design and results: Blood samples from 440 patients, who were either admitted with acute coronary syndromes or worsening heart failure, or who were heart failure outpatients, were evaluated. The relation between the two assays was analysed and the diagnostic concordance calculated. A good correlation was found between the assays (r = 0.96, 95% CI: 0.94–0.97) with a diagnostic concordance of 93%. A separate analysis was performed in the range where most clinical decisions are made (60–3000ng/L), with a diagnostic concordance of 88%. The usefulness in a clinical setting where time is important was high.

Conclusion: The Roche Cardiac Reader® NT-proBNP assay has been evaluated in a clinical setting. The point-of-care method shows good results, although with a restricted analytical range, compared with the reference.

Key Words: Natriuretic peptides • Point-of-care • Heart failure

Received March 11, 2007; Revised November 16, 2007; Accepted January 9, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.